@article{TCR31533,
author = {Jing Qin and Daxiong Zeng and Fajun Xie and Ruoying Yu and Xue Wu and Kaihua Liu and Yang W. Shao and Hongyang Lu and Junhong Jiang},
title = {Rare GCC2-ALK fusion G13:A20 detected by next generation sequencing in non-small cell lung cancer patients and treatment response},
journal = {Translational Cancer Research},
volume = {8},
number = {5},
year = {2019},
keywords = {},
abstract = {Two patients with rare GCC2-ALK fusion G13:A20 which were found in Chinese population by next generation sequencing (NGS) developed resistant to crizotinib with a prolonged progression-free survival (PFS). Both patients showed unfavorable response to subsequent second or third generation tyrosine kinase inhibitors (TKIs) treatment with shorten PFS. In conclusion, non-small cell lung cancer (NSCLC) patients with rare GCC2-ALK fusion G13:A20 may be optimal candidates for crizotinib as front-line therapy and may have a high possibility to exhibit unsatisfactory response to subsequent second or third generation TKIs target therapy after acquiring resistance to crizotinib.},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/31533}
}